Effect of a Specific Phenolic Compound on Blood Pressure (PHENOLPRESS)

Technological Centre of Nutrition and Health, Spain

Status and phase: Unknown; Phase 3

Conditions: Cardiovascular Risk Factors; Blood Pressure

Treatments: Dietary Supplement: phenolic compound; Dietary Supplement: placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT02628353

LLAVOR 2014-00081

Details and patient eligibility

About

The study's main objective is to investigate the effects of acute consumption of a preparation containing 100 mg of a specific phenolic compound (patent pending, P201531587) on systolic BP after ingestion of a high fat meal.

Full description

The study's main objective is to investigate the effects of acute consumption of a preparation containing 100 mg of a specific phenolic compound (patent pending, P201531587) on systolic blood pressure (BP) after ingestion of a high fat meal.

The secondaries objectives are:

• To evaluate the effects on diastolic BP.
• To study the phenolic compound bioavailability and to analyze its metabolites for determine the phenolic compound consumption biomarkers.
• To evaluate the effects on endothelial function by ischemic reactive hyperemia (IRH).

The sample size was calculated using a previous studies using systolic blood pressure (SBP) as the primary outcome measure. A total of 14 subjects are needed, assuming variance components of approximately 20.0, to detect differences between treatments (placebo and phenolic product) of 10 mmHg, with a bilateral significance level of α=0.05, a power of 80% and a standard deviation of 11.82 mmHg at the baseline.

To compare the main variable efficiency of the products of study as well as secondary variables of efficiency, will carry out analysis of the covariance (ANCOVA) with basal value as covariable, followed by the Tukey test for determining multiple differences. All tests will be carried out with significance to bilateral level of 5%. It is considered significant value p<0,05. The data will be analyzed using the "SPSS" program version 22.

The statistical analysis will follow the principles specified in the guidelines of the International Conference on Harmonization (ICH) E9 and CPMP/EWP/908/99 ICH E9 Points to Consider on Multiplicity Issues in Clinical Trials.

Enrollment: 11 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Adults men or women (>18 years old)
• Blood pressure (with no drug intervention) ≥130 mm Hg systolic blood pressure ≤ 159 mmHg
• No evidence of chronic disease
• Written informed consent provided before the initial screening visit.

Exclusion criteria

• Systolic blood pressure ≥ 160 mm Hg and diastolic blood pressure ≥100 mm Hg or taking antihypertensive medication
• Body mass index (BMI) ≥ 35 kg/m2
• Glucose (fasting state) >125 mg/dL
• LDL-cholesterol >189 mg/dL
• Triglycerides >350 mg/dL
• Pregnant or intending to become pregnant
• Use of medication, antioxidant, or multi-vitamin supplements
• Chronic alcoholism
• Intense physical activity (5h/week)
• Intestinal disorders
• Following of a vegetarian diet
• Anemia (hemoglobin ≤13 g/dL in men and ≤12 g/dL in women)
• Being intolerant or suffer from allergy to any of the products of the high fat meal (white bread, olive oil, boiled egg, cheese) or to the products of the study.
• Current or past participation in a clinical trial or consumption of a research product in the 30 days prior to inclusion in the study.
• Failure to follow the study guidelines.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

11 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

control group

Treatment:

Dietary Supplement: placebo

Phenolic compound

Experimental group

Description:

treated group

Treatment:

Dietary Supplement: phenolic compound